Muted action for GSK stock as price tests GBX 1,806.00 support

Traders Union
All News
Financial News
GSK slides 0.69% to GBX1,873.00 today

Highlights

GSK posted a 5.7% year-on-year increase in Q4 net profit to approximately Rs 278 crore, supported by sustained product demand.
The Board recommended a final dividend of Rs 57 per equity share for FY26, pending shareholder approval at the annual meeting.
Shares trade below key short- and medium-term moving averages with momentum indicators signaling persistent selling, but a modest rebound to Rs 1,892.00–1,918.00 is likely over the next five days.

Dividend proposal and profit growth countered by persistent selling pressure

GSK released its audited financial results for the fourth quarter and full year ended March 31, 2026, highlighting a 5.7% year-on-year rise in Q4 net profit to approximately Rs 278 crore. Quarterly revenue was reported at Rs 995.3 crore, reflecting a modest 2.1% increase compared to the prior year and underscoring sustained product demand during the period. The Board also recommended a final dividend of Rs 57 per equity share for FY26, subject to shareholder approval at the upcoming annual meeting, though price action has remained under broader selling pressure.

Technical resistance and negative momentum reinforce intraday weakness

GBX 1,873.00 is currently positioned below both the 20-day SMA at GBX 1,982.10 and the 50-day SMA at GBX 2,033.90, while holding above the 200-day SMA support level at GBX 1,806.25. The Ichimoku Kijun lies at GBX 2,012.00, serving as immediate resistance for any rebound attempts. Momentum indicators remain largely negative: D1 MACD and ADX confirm ongoing selling interest, with RSI at 36.10, CCI at -66.74, and BBP at -20.97 suggesting mild oversold conditions and sustained intraday seller dominance. Oscillators are mixed, with Stoch RSI in a neutral stance and the Awesome Oscillator showing neither reversal nor confirmation, indicating a contrast between short-term stabilization and underlying weakness.

Rebound odds rise while resistance and support levels define risk

Looking ahead to the next five trading days, GSK is expected to trade within the GBX 1,892.00 to GBX 1,918.00 range, which reflects the typical volatility band relative to current levels. There is a calculated probability of over 80% for a price rebound in this period, with limited downside potential implied by prevailing technical factors. A break and close above the Kijun resistance at GBX 2,012.00 would be needed to initiate a bullish scenario, while a move below the GBX 1,806.00 support mark would confirm renewed selling momentum.

Anton Kharitonov, expert at Traders Union, sees the latest financials from GSK as modestly positive, but the share price remains weak. He notes that technical signals are still dominated by selling pressure, with no confirmation of a true reversal. Until price regains the 20-day or at least clears the Kijun at GBX 2,012.00, the backdrop stays fragile. "Unless GSK breaks above GBX 2,012.00, I remain defensive and see no actionable long setup here."

Earlier, analysts noted that GSK faced ongoing technical challenges and persistent downside momentum despite supportive developments from international partnerships. With fresh financial results now highlighting continued earnings growth but price action still under pressure, traders should closely monitor whether a sustained move above the Ichimoku Kijun at GBX 2,012.00 materializes to signal any meaningful shift in trend.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.